The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study evaluating olutasidenib in patients with IDH1-mutated clonal cytopenia of undetermined significance or lower-risk myelodysplastic syndromes/chronic myelomonocytic leukemia.
 
Kelly Chien
Honoraria - Abbvie
Consulting or Advisory Role - Rigel
 
Jeremy Ramdial
No Relationships to Disclose
 
Wei Qiao
No Relationships to Disclose
 
Lizabeth Romero
No Relationships to Disclose
 
Guillermo Montalban-Bravo
No Relationships to Disclose
 
Nicholas Short
Honoraria - Amgen
Consulting or Advisory Role - Amgen; AstraZeneca; NGM Biopharmaceuticals; Novartis; Pfizer; Takeda
Research Funding - Astellas Pharma; Stemline Therapeutics; Takeda
 
Ghayas Issa
Consulting or Advisory Role - Abbvie; Kura Oncology; Novartis; NuProbe; Sanofi; Syndax
Research Funding - Astex Pharmaceuticals (Inst); Cullinan Oncology; Kura Oncology (Inst); Merck; Novartis (Inst); NuProbe (Inst); Syndax (Inst)
 
Farhad Ravandi-Kashani
Honoraria - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Jazz Pharmaceuticals; Novartis; Pfizer; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Certara Inc; Jazz Pharmaceuticals; Syros Pharmaceuticals; Taiho Oncology
Research Funding - Amgen; Astellas Pharma (Inst); Astex Pharmaceuticals; Biomea Fusion; Bristol-Myers Squibb; Cellerant; Macrogenics; Prelude Therapeutics; Selvita; Syros Pharmaceuticals; Taiho Oncology; Xencor
 
Naval Daver
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Abbvie; Agios; Amgen; Arog; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; Gilead Sciences; Immunogen; Jazz Pharmaceuticals; Kite, a Gilead company; Novartis; Pfizer; SERVIER; Shattuck Labs; Stemline/Menarini; Syndax; Trillium Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); FATE Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Glycomimetics (Inst); Hanmi (Inst); Immunogen (Inst); Kite, a Gilead company (Inst); Novimmune (Inst); Pfizer (Inst); Servier (Inst); Trillium Therapeutics (Inst); Trovagene (Inst)
 
Tapan Kadia
Honoraria - CURE
Consulting or Advisory Role - Abbvie/Genentech; Agios; Bristol-Myers Squibb/Celgene; Daiichi Sankyo/UCB Japan; Jazz Pharmaceuticals; Liberum; Novartis; Pfizer; Pinot Bio; Sanofi; Sellas Life Sciences; SERVIER
Research Funding - Abcuro; Amgen; Ascentage Pharma; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; BiolineRx; Bristol-Myers Squibb; Celgene; cellenkos; Cyclacel; DAAN Biotherapeutics; Delta-Fly Pharma; Genentech/Abbvie; Genfleet Therapeutics; Glycomimetics; Incyte; Iterion Therapeutics; Jazz Pharmaceuticals; Pfizer; Pulmotech; Regeneron (Inst); Sellas Life Sciences
 
Hagop Kantarjian
Honoraria - Abbvie; Amgen; Ascentage Pharma Group; Daiichih-Sankyo (Inst); Immunogen (Inst); Ipsen; KAHR Medical; Novartis; Pfizer; Shenzhen Target Rx
Consulting or Advisory Role - Abbvie
Research Funding - Abbvie (Inst); Amgen (Inst); Ascentage Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Lilly (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst)
 
Guillermo Garcia-Manero
Honoraria - Ascentage Pharma; Bristol-Myers Squibb/Celgene; Curis; Keros Therapeutics; SERVIER; Taiho Oncology
Consulting or Advisory Role - Ascentage Pharma; Bristol-Myers Squibb; Curis; Keros Therapeutics; SERVIER; Taiho Oncology
Research Funding - Abbvie; Bristol-Myers Squibb; Chordia Therapeutics; Curis; Genentech; Jazz Pharmaceuticals; Novartis; Rigel; Stemline Therapeutics; Taiho Oncology; Zentalis
 
Courtney Dinardo
Honoraria - Abbvie; Astellas Pharma; Bristol Myers Squibb Foundation; Daiichi Sankyo/Astra Zeneca; Ellipses Pharma; Genentech/Abbvie; GlaxoSmithKline; Schrodinger; SERVIER
Consulting or Advisory Role - Abbvie; AstraZeneca; Genmab; Molecular Partners; Rigel; Ryvu Therapeutics; Schrodinger; SERVIER
Research Funding - Abbvie; Astex Pharmaceuticals; BeiGene; Bristol-Myers Squibb/Celgene; Cleave Therapeutics; Foghorn Therapeutics; Immune-Onc Therapeutics; Jazz Pharmaceuticals; Loxo/Lilly; Remix Therapeutics; SERVIER